Modifications of health care paradigm required by personalized medicine

Conversatory class
Speaker and affiliation: 
Dr. Jacek Graliński - Public Affairs Director, AstraZeneca Pharma Poland, Sp. z o. o.
Thu, 2015-11-26 10:30
Conference room in the Świerk Science & Technology Park

Personalized medicine consists in selecting treatment strategies most applicable at right times for specific groups of patients using some molecular criteria, and/or in determining their molecular predispositions for specific diseases in order to identify proper prevention measures well ahead of time. Practically subgroups of patients with similar molecular biomarkers (e.g. specific mutations) are identified  among all patients suffering a given illness. Targeted therapy that might be individually matched to each such subgroup is usually more efficient and safe than the “one-size-fits-all” therapy applied so far. The new approach can potentially bring numerous benefits for both patients and physicians, as well as for national health care systems. However, mentality of system managers would have to be significantly changed, and portfolio of available management tools and their usage methodology would have to be developed.


The seminar will be held in Science & Technology Park building conference room in Świerk. NCBJ bus leaves to Świerk at 10.15 am from entrance gate to the Hoża 69 premises in Warsaw.
Professor Ludwik Dobrzyński